Thus, with its ability to reduce glucose metabolism and inhibit NFkB, GP-2250 might preferentially target CD133+ cells and/or reduce the amount of CD133 in the cells, thereby sensitizing the tumor in whole to Gemcitabine. The gene discussed is PROM1; the disease is neoplasm.